PDCD1 and lung carcinoma: Moreover, to increase the immunotherapy testing speed of in vitro platform, Ding et al. developed an automated microfluidic droplet platform that can rapidly generate considerable amount of lung cancer PDO and reliably evaluate the efficacy of PD-1 blockade, bispecific therapy, and T-cell therapy on patients within 7–14 days [53].